Treatment options

The goals of treatment in patients with HF are to improve their clinical status, functional capacity and quality of life, prevent hospital admission and reduce mortality. Neuro-hormonal antagonists (ACEIs, MRAs and beta-blockers) have been shown to improve survival in patients with HFrEF and are recommended for the treatment of every patient with HFrEF, unless contraindicated or not tolerated. A new compound (sacubitril/valsartan) that combines the moieties of an ARB (valsartan) and a neprilysin(NEP) inhibitor (sacubitril) has been shown to be superior to an ACEI (enalapril) in reducing the risk of death and of hospitalization for HF. Sacubitril/valsartan is therefore recommended to replace ACEIs in ambulatory HFrEF patients who remain symptomatic despite optimal therapy.^1,2

Guidelines for diagnosis and treatment of acute and chronic heart failure
Discover the guidelines here